diabeticmediterraneandiet.com
Drug Review: SGLT2 Inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin)
In March, 2013, the U.S. Food and Drug Administration approved the first agent in a new class of diabetes drugs: canagliflozin. It’s sold in the U.S. as Invokana. So we now have 12 classes of…